NCT05363618View on ClinicalTrials.gov

Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn

NACompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Heartburn
Interventions
DIETARY_SUPPLEMENT

Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)

Active study product

OTHER

Placebo 1.4 ml

Placebo

Trial Locations (1)

20109

Microbiome Health Sciences, Manassas

Sponsors
All Listed Sponsors
lead

Microbiome Health Sciences

INDUSTRY